Tretinoin is a Small Molecule owned by Ortho Dermatologics, and is involved in 18 clinical trials, of which 16 were completed, and 2 are ongoing.

Tretinoin activates isoforms of retinoic acid (RAR) nuclear receptors including (RAR alpha, RAR beta, and RAR gamma) which may act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation.

The revenue for Tretinoin is expected to reach a total of $243m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tretinoin NPV Report.

Tretinoin is currently owned by Ortho Dermatologics. Bausch Health Companies is the other company associated in development or marketing of Tretinoin.

Tretinoin Overview

Tretinoin (Altreno) all-trans-retinoic acid which is a naturally occurring derivative of VitaminA (retinol). It is formulated as lotion for topical application. Altreno is indicated for the topical treatment of acne vulgaris.

Bausch Health Companies Overview

Bausch Health Companies (Bausch Health), formerly Valeant Pharmaceuticals International Inc, is engaged in the manufacturing, development, and marketing of a range of medical devices, over-the-counter products (OTC), and pharmaceutical products. Bausch Health offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in various regions across the world including the US, Canada, Africa, Middle East, Australia, Latin America, and Europe. It also operates manufacturing facilities in the US, Brazil, Columbia, Germany, Canada, among others. Bausch Health is headquartered in Laval, Quebec, Canada.

The company reported revenues of (US Dollars) US$8,434 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 4.6%, compared to an operating margin of 7.7% in FY2020. The net loss of the company was US$948 million in FY2021, compared to a net loss of US$560 million in FY2020. The company reported revenues of US$2,046 million for the third quarter ended September 2022, an increase of 4% over the previous quarter.

Quick View – Tretinoin

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Tretinoin
Administration Pathway
  • Topical
Therapeutic Areas
  • Dermatology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.